IMRN
NASD Immuron Limited Sponsored ADR$1.04 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.04, $0.02 below the day’s high of $1.06
- YTD change
- +36.39%
- vs 20-day SMA
- -11.13%
- vs 200-day SMA
- +3.09%
Price ranges
Price & Performance
+0.25 (+32.23%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 96.4% away from all-time highs of $28.99
- IMRN is up 36% since the beginning of the year
- IMRN is down 50% over the past 12 months
- IMRN is down 28% over the past 1 month
IMRN reads poor: price sits above one of the two key moving averages, the 12-month move is -50.0%.
- Previous minute
- +$0.00
- Last hour
- +$0.03
- Last 5 days
- -4.59%
- vs 8-day SMA
- -5.56%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. Its proprietary technology is based on polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum. This technology can be used to target viruses or bacteria and neutralize the toxins they produce on mucosal surfaces. It operates through the Research and Development, and Hyperimmune Products segments. The Research and Development segment includes projects performed in Australia and United States. The Hyperimmune Products segment is composed of Travelan, and Protectyn activities which occur in Australia, United States, and rest of the world. The company was founded on January 13, 1994, and is headquartered in Carlton, Australia.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
